Drug Profile
Research programme: hepatitis B virus inhibitors - Bayer
Alternative Names: Hepatitis B virus inhibitors research programme - BayerLatest Information Update: 08 Nov 2006
Price :
$50
*
At a glance
- Originator Bayer
- Class
- Mechanism of Action Hepatitis B virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hepatitis B
Most Recent Events
- 08 Nov 2006 Discontinued - Preclinical for Hepatitis B treatment in Germany (unspecified route)
- 06 Dec 2002 Preclinical trials in Hepatitis B treatment in Germany (unspecified route)